To test this hypothesis, we used an FDA-approved highly specific JAK1/JAK2 inhibitor ruxolitinib (common brand name: Jakafi; indicated as “Ruxo” in Fig. 5) in SUIT-2 cells transfected with siSCR or siMETTL3 (Fig. 5A; 48 h siRNA treatment, followed by 1 h VSV-ΔM51 infection). Here, JAK1 is linked to infection.